Recent developments in crystal-induced inflammation pathogenesis and management

Current Rheumatology Reports

Volumn 9, Issue 3, 2007, Pages 243-250

  Lioté, Frédéric ^a   Ea, Hang Korng ^b  

^a HÔPITAL LARIBOISIÈRE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BENZBROMARONE; CALCIUM PHOSPHATE; CALCIUM PYROPHOSPHATE; COLCHICINE; DICLOFENAC; ETORICOXIB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; METHOTREXATE; MYELOID DIFFERENTIATION FACTOR 88; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; STEROID; SULFINPYRAZONE; TENOXICAM; TOLL LIKE RECEPTOR; URATE; URICOSURIC AGENT; XANTHINE OXIDASE INHIBITOR;

ASPIRATION; AUTOCRINE EFFECT; CALCIUM SIGNALING; CARDIOTOXICITY; CELL ACTIVATION; CLINICAL TRIAL; CRYSTALLIZATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEHYDRATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; GOUT; HUMAN; INFLAMMATION; INFLAMMATORY CELL; INNATE IMMUNITY; LIVER TOXICITY; LOW DRUG DOSE; META ANALYSIS; NONHUMAN; PARACRINE SIGNALING; PSEUDOGOUT; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATIC DISEASE; SYNOVIAL FLUID LEVEL; SYSTEMATIC REVIEW; TOXICITY; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL; VOMITING;

CHONDROCALCINOSIS; EVIDENCE-BASED MEDICINE; GOUT; HUMANS; INFLAMMATION; URIC ACID;

EID: 34250731657     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-007-0039-5     Document Type: Review

References (38)

1. Lioté F, Ea HK: Pathogenesis of crystal-induced inflammation. Rev Rhum 2007, 74:131-137.
2. Liu-Bryan R, Lioté F: Monosodium urate and calcium pyrophosphate dihydrate (CPPD) crystals, inflammation, and cellular signaling. Joint Bone Spine 2005, 72:295-302.
3. Ea HK, Uzan B, Rey C, Lioté F: Octacalcium phosphate crystals directly stimulate expression of inducible nitric oxide synthase through p38 and JNK mitogen-activated protein kinases in articular chondrocytes. Arthritis Res Ther 2005, 7:R915-926.
4. Fujiwara K, Ohkawara S, Takagi K, et al.: Involvement of CXC chemokine growth-related oncogene-alpha in monosodium urate crystal-induced arthritis in rabbits. Lab Invest 2002, 82:1297-1304.
5. •• Choi HK, Mount DB, Reginato AM: Pathogenesis of gout. Ann Intern Med 2005, 143:499-516. A comprehensive and clear review with outstanding figures on the pathogenesis of gout.
6. Tramontini N, Huber C, Liu-Bryan R, et al.: Central role of complement membrane attack complex in monosodium urate crystal-induced neutrophilic rabbit knee synovitis. Arthritis Rheum 2004, 50:2633-2639.
7. Shi Y, Evans JE, Rock KL: Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003, 425:516-521.
8. Rock KL, Hearn A, Chen CJ, et al.: Natural endogenous adjuvants. Spinger Semin Immunopathol 2005, 26:231-246.
9. •• Liu-Bryan R, Scott P, Sydlaske A, et al.: Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2005, 52:2936-2946. MyD88 and TLR2/4 could be implicated in the first signaling events triggered by naked MSU crystals. Debated through Scott et al. [12••].
10. Grandjean-Laquerriere A, Tabary O, Jacquot J, et al.: Involvement of toll-like receptor 4 in the inflammatory reaction induced by hydroxyapatite particles. Biomaterials 2007, 28:400-404.
11. Liu-Bryan R, Pritzker K, Firestein GS, Terkeltaub R: TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monodium urate crystal-induced nitric oxide generation. J Immunol 2005, 174:5016-5023.
12. •• Scott P, Ma H, Viriyakosol S, et al.: Engagement of CD14 mediates the inflammatory potential of monosodium urate crystals. J Immunol 2006, 177:6370-6378. A demonstration for the role of CD14, as a ligand, between TLR and MSU crystals.
13. •• Chen CJ, Shi Y, Hearn A, et al.: MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 2006, 116:2262-2271. A debatable role for the TLR system in stimulating crystal-induced inflammation in vivo. A central role for MyD88 and the IL-1 receptor pathway.
14. •• Martinon F, Petrilli V, Mayor A, et al.: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241. A demonstration for inflammasome activation using several knockout mice for the components of the docking activation platform for caspase-1 activation by MSU crystals. The real interaction between MSU and CPPD crystals and the inflammasome is till unclear.
15. Murakami Y, Akohoshi T, Hayashi T, et al.: Induction of triggering receptor expressed on myeloid cells 1 in murine resident peritoneal macrophages by monosodium urate monohydrate crystals. Arthritis Rheum 2006, 54:455-464.
16. Liu-Bryan R, Terkeltaub R: Evil humors take their Toll as innate immunity makes gouty joints TREM-ble. Arthritis Rheum 2006, 54:383-386.
17. Tschopp J, Martinon F, Burns K: NALPS: a novel protein family involved in inflammation. Nat Rev Mol Cell Biol 2003, 4:95-104.
18. Martinon F, Tschopp J: NLRs join TLRs as innate sensors of pathogens. Trends Immunol 2005, 26:447-454.
19. Rose DM, Liu-Bryan R: Innate immunity in triggering and resolution of acute gouty inflammation. Curr Rheumatol Rep 2006, 8:209-214.
20. Landis RC, Yagnik DR, Florey O, et al.: Safe disposal of inflammatory monosodium urate monohydrate crystals by differenciated macrophages. Arthritis Rheum 2002, 46:3026-3033.
21. Lioté F, Ea HK: Gout: update on some pathogenic and clinical aspects. Rheum Dis Clin North Am 2006, 32:295-311, vi.
22. • Rose DM, Sydlaske AD, Agha-Babakhani A, et al.: Transglutaminase 2 limits murine peritoneal acute gout-like inflammation by regulating macrophage clearance of apoptotic neutrophils. Arthritis Rheum 2006, 54:3363-3371. Tgase 2 is implicated in the upstream signaling events after apoptotic bodies stimulation of macrophages leading to an anti-inflammatory signal.
23. •• Zhang W, Doherty M, Bardin T, et al.: EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312-1324. A comprehensive review by clinical experts and evidence-based medicine specialists for gout diagnosis and management.
24. Schlesinger N, Detry MA, Holland BK, et al.: Local ice therapy during bouts of acute gouty arthritis. J Rheumatol 2002, 29:331-334.
25. Schlesinger N: Response to application of ice may help differentiate between gouty arthritis and other inflammatory arthritides. J Clin Rheumatol 2006, 12:275-276.
26. • Niel E, Scherrmann JM: Colchicine today. Joint Bone Spine 2006, 73:672-678. A comprehensive review on the pharmacology and pharmacokinetics of colchicine by scientists who developed the anticolchicine antibody.
27. Rubin BR, Burton R, Navarra S, et al.: Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout. Arthritis Rheum 2004, 50:598-606.
28. Juhlin T, Bjorkman S, Gunnarsson B, et al.: Acute administration of diclofenac, but possibly not long term low dose aspirin, causes detrimental renal effects in heart failure patients treated with ACE-inhibitors. Eur J Heart Fail 2004, 6:909-916.
29. Rull M, Clayburne G, Sieck M, Schumacher HR: Intra-articular corticosteroid preparations: different characteristics and their effect during inflammation induced by monosodium urate crystals in the rat subcutaneous air pouch. Rheumatology (Oxford) 2003, 42:1093-1100.
30. Getting SJ, Christian HC, Flower RJ, Perretti M: Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum 2002, 46:2765-2775.
31. Neogy T, Hunter DJ, Chasson CE, et al.: Frequency of innapropriate management of gout attacks. Arthritis Rheum 2004, 50:S339.
32. Fang W, Zeng X, Li M, et al.: The management of gout at an academic healthcare center in Beijing: a physician survey. J Rheumatol 2006, 33:2041-2049.
33. Perez-Ruiz F, Lioté F: Lowering sUA levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Care Res 2007, in press.
34. Richy F, Bruyere O, Ethgen O, et al.: Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 2004, 63:759-766.
35. Alejandro A, Spilberg I: Colchicine prophylaxis in pseudogout. J Rheumatol 1986, 13:804-805.
36. • Chollet-Janin A, Finckh A, Dudler J, Guerne PA: Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. Arthritis Rheum 2007, 56:688-692. A short series suggesting an anti-inflammatory and preventive effect of low-dose MTX in chronic relapsing CPPD attacks.
37. Getting SJ: Targeting melanocortin receptors as potential novel therapeutics. Pharmacol Ther 2006, 111:1-15.
38. Schlesinger N, Schumacher R, Catton M, Maxwell L: Colchicine for acute gout. Cochrane Database Syst Rev 2006, (4):CD006190.